Does Blue Cross Blue Shield of Michigan Cover Eliquis?

What Eliquis Is and Why Formulary Placement Matters

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, interrupting the coagulation cascade before thrombin is formed. The FDA approved it in December 2012 for stroke prevention in nonvalvular atrial fibrillation, and the agency later added indications for deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and surgical DVT prophylaxis [1].

Because anticoagulation therapy directly reduces stroke and thromboembolic mortality, the decision about which drug a plan covers is not a minor administrative detail. It has real clinical consequences.

The Clinical Evidence Behind Apixaban

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to dose-adjusted warfarin in patients with nonvalvular atrial fibrillation. Apixaban produced a 21% relative risk reduction in stroke or systemic embolism (P<0.001), a 31% reduction in major bleeding (P<0.001), and an 11% reduction in all-cause mortality (P=0.047) [2]. These results are why the 2023 ACC/AHA Atrial Fibrillation Guideline gives apixaban a Class I recommendation for most AF patients requiring anticoagulation [3].

For DVT and PE, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional enoxaparin-plus-warfarin therapy for recurrent VTE, with a 69% relative risk reduction in major bleeding (P<0.001) [4]. The numbers are not abstract; they inform why physicians push back when insurers restrict access.

Why Tier Placement Affects Your Monthly Cost

BCBSM uses a multi-tier drug formulary. Tier 1 is generic drugs at the lowest copay. Tier 2 covers preferred generics. Tier 3 covers preferred brand-name drugs. Tier 4 covers non-preferred brands at higher cost-sharing, and Tier 5 (on some plans) covers specialty drugs at the highest cost-sharing [5].

Eliquis historically landed at Tier 3 or Tier 4 on BCBSM commercial plans. At Tier 3, a 30-day supply might cost $50, $100 after meeting the deductible; at Tier 4 it can climb to $100, $200 or more depending on the specific plan. Exact amounts vary by employer group contract, so the only definitive number is the one on your Summary of Benefits.

How BCBSM Formularies Are Organized for Eliquis

BCBSM operates several distinct product lines: PPO (including the statewide Blue Plan), HMO (Blue Care Network), Medicare Advantage (MA) plans, and Medicaid Managed Care. Each has its own pharmacy formulary, and Eliquis placement differs across them.

Commercial PPO and Blue Care Network HMO

On most BCBSM commercial PPO plans, Eliquis is listed as a covered drug subject to prior authorization (PA). Step therapy, requiring documentation that the member tried warfarin (or another anticoagulant) first, is applied on some employer group contracts but not all [6]. If step therapy applies and a physician documents a clinical reason to skip it (e.g., a patient with highly variable INR on warfarin, pregnancy, or renal parameters that favor a DOAC), the plan must review that exception request within 72 hours for non-urgent cases.

Blue Care Network (BCN), the HMO arm of BCBSM, manages its own Drug Formulary. BCN generally mirrors the PPO formulary structure for Eliquis but may apply more restrictive step-therapy requirements on select employer contracts.

Medicare Advantage Plans

BCBSM offers multiple Medicare Advantage products in Michigan. On Medicare Part D formularies, Eliquis is classified on the formulary of virtually all MA-PD plans because CMS requires plans to cover at least two drugs per drug class [7]. CMS 2024 data show that Eliquis appears on 97% of Part D stand-alone drug plan formularies nationally.

Under Medicare Part D, cost-sharing for Tier 3 or Tier 4 drugs may reach $47, $100 per 30-day fill during the initial coverage phase, then shift once the member moves through the deductible and into the catastrophic coverage phase. Starting January 1, 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year, which substantially reduces catastrophic-phase costs for patients on long-term Eliquis therapy [8].

Authorized Generic: A Lower-Tier Path

Bristol-Myers Squibb launched an authorized generic of apixaban in 2023. Some BCBSM plans have moved the authorized generic to Tier 2, reducing copays to the preferred-generic level. If your formulary lists both "apixaban (generic)" and "Eliquis (brand)," ask your pharmacist to dispense the authorized generic. The molecule is chemically identical to the brand-name product.

Prior Authorization: What BCBSM Requires

Prior authorization for Eliquis under BCBSM plans generally requires your physician to document one or more approved clinical indications: nonvalvular atrial fibrillation, DVT treatment, PE treatment, or surgical DVT prophylaxis [9]. The PA form also typically asks for:

• Diagnosis code (ICD-10) confirming the covered indication
• CHA2DS2-VASc score for atrial fibrillation cases (a score of 2 or higher in men, 3 or higher in women supports anticoagulation per AHA/ACC guidelines) [3]
• Current renal function (serum creatinine or eGFR), because dose adjustment to 2.5 mg twice daily applies when two of three criteria are met: age 80 or older, weight 60 kg or less, or creatinine 1.5 mg/dL or higher [1]
• Contraindication or intolerance to warfarin if step therapy applies

Most PA decisions are returned within 1 to 3 business days for non-urgent requests. Urgent requests (inpatient or same-day clinical need) must be answered within 24 to 72 hours under Michigan's Insurance Code PA standards [10].

What to Do If the PA Is Denied

A denial is not final. Michigan law requires BCBSM to provide a written explanation of any PA denial. Your physician can submit a peer-to-peer review request, during which the treating cardiologist or internist speaks directly with the plan's medical reviewer. If that fails, a formal appeal follows. Data from the Kaiser Family Foundation show that 59% of internal appeals of insurer drug denials result in a full or partial reversal [11].

An expedited external review is available through the Michigan Department of Insurance and Financial Services (DIFS) when standard timelines would seriously jeopardize health. External review decisions in Michigan are binding on the insurer.

Step Therapy Exceptions

Michigan passed step therapy reform legislation that took effect in 2020. Under Public Act 341 of 2019, commercial health plans regulated in Michigan must grant a step-therapy exception when a prescribing physician documents that the required step-therapy drug is contraindicated, has previously been tried and failed, or would cause clinically significant harm [12]. This means that if warfarin is genuinely unsuitable for a patient (e.g., due to inability to maintain therapeutic INR, dietary restrictions, or drug interactions), the insurer must waive the step and approve Eliquis.

Cost-Reduction Options for BCBSM Members

Even with coverage, the Tier 3 or Tier 4 cost-sharing can be substantial over 12 months of therapy.

Bristol-Myers Squibb Savings Card

BMS offers a savings card for commercially insured patients through the Eliquis 360 Support program. Eligible patients pay as little as $10 per 30-day supply, with a maximum savings of $6,400 per year. Patients on Medicare or Medicaid are not eligible for this card, but other programs exist for them [13].

Patient Assistance Program

The BMS Access Support program provides free Eliquis to uninsured or underinsured patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level). Applications are submitted by the physician's office on the patient's behalf.

GoodRx and Cash-Pay Pricing

For patients who find it cheaper to pay cash than to run the claim through insurance, GoodRx and similar platforms often list the authorized generic apixaban at $80, $140 per 30-day supply at major Michigan pharmacies. Paying cash means the cost does not count toward the insurance deductible, so this approach works best for patients who have already met their deductible or who use a health savings account (HSA) for drug purchases.

90-Day Mail-Order Supplies

BCBSM's mail-order pharmacy (Prime Therapeutics) typically reduces the per-day cost of a 90-day supply of Tier 3 drugs. For a patient with a $75 Tier 3 copay per 30-day fill, the 90-day mail-order copay is often $150 rather than $225, saving $75 per quarter.

Clinical Considerations: Who Needs Eliquis Specifically

Not every anticoagulation indication requires Eliquis. The choice between apixaban, rivaroxaban (Xarelto), dabigatran (Pradaxa), and warfarin depends on the clinical picture.

Atrial Fibrillation

For nonvalvular AF, all four DOACs carry Class I recommendations in the 2023 ACC/AHA guidelines [3]. Apixaban's edge is its bleeding profile. In ARISTOTLE, the rate of intracranial hemorrhage with apixaban was 0.33% per year versus 0.80% per year with warfarin, a relative reduction of 58% (P<0.001) [2]. For patients at elevated bleeding risk (e.g., elderly, history of falls, prior GI bleed), that difference may steer the prescriber toward apixaban specifically, which strengthens a medical necessity argument for PA.

VTE Treatment and Prophylaxis

The AMPLIFY-EXT trial (N=2,482) tested apixaban 2.5 mg twice daily as extended VTE prophylaxis beyond 6 months. Compared to placebo, apixaban reduced recurrent VTE by 67% (P<0.001) with no statistically significant increase in major bleeding [14]. This extended-prophylaxis indication is less commonly pre-authorized; physicians may need to submit additional documentation for durations beyond 6 months.

Renal Impairment

Apixaban is 27% renally cleared, making it one of the safer DOACs in patients with chronic kidney disease. The 2022 KDIGO guidelines on CKD and cardiovascular risk note that apixaban may be preferred over rivaroxaban or dabigatran in patients with eGFR 15 to 29 mL/min/1.73m² because of its lower renal clearance fraction [15]. A patient with both AF and CKD Stage 4 has a strong pharmacological rationale for apixaban specifically, which BCBSM's PA reviewers should weigh when evaluating a medical necessity claim.

A Decision Framework for Choosing Eliquis vs. Alternatives Under BCBSM

When the formulary lists both apixaban and rivaroxaban, clinicians and patients can use the following criteria to determine whether a medical necessity exception for apixaban is clinically supported:

1. Bleeding risk: HAS-BLED score 3 or higher favors apixaban given ARISTOTLE's intracranial hemorrhage data.
2. Twice-daily dosing adherence: Patients with documented adherence barriers may be better suited to once-daily rivaroxaban, which BCBSM may cover at a lower tier on some plans.
3. Renal function: eGFR <30 mL/min/1.73m² is a relative contraindication to dabigatran; apixaban is the preferred agent per KDIGO [15].
4. Drug interactions: Apixaban has fewer CYP3A4 interactions than rivaroxaban; patients on strong CYP3A4 inducers (e.g., rifampin, phenytoin) should avoid all DOACs, but this affects the apixaban vs. Rivaroxaban choice less than dabigatran vs. Apixaban.
5. Cost tier: If the authorized generic apixaban is available at Tier 2 on the member's specific plan, cost-sharing may actually favor apixaban over brand rivaroxaban.

Navigating the BCBSM Appeals Process Step by Step

If your PA is denied and your physician's peer-to-peer review fails, the formal internal appeal must be filed within the timeframe stated in the denial letter (typically 180 days). Submit all of the following:

• A letter of medical necessity from the prescribing physician referencing specific guideline language (citing the 2023 ACC/AHA AF guidelines or AMPLIFY/ARISTOTLE trial data is appropriate) [3]
• Laboratory values supporting dose selection (INR history if warfarin was tried, eGFR, weight, age)
• Any evidence of adverse effects from the step-therapy drug
• A copy of Michigan Public Act 341 of 2019 if step therapy is the contested requirement [12]

BCBSM must provide a written decision on an internal appeal within 30 days for non-urgent matters, or 72 hours for urgent matters. If the internal appeal fails, an independent external review through DIFS is the next step. External reviewers are required by Michigan law to be board-certified in a specialty relevant to the condition at issue.

Medicare Part D Members: Special Considerations

For BCBSM Medicare Advantage members, the rules differ from commercial plans because CMS governs Part D formulary requirements directly.

Coverage Determination vs. Exception

Under CMS regulations, a "coverage determination" for a Tier 3 drug on a Part D plan can be requested when the drug is listed on the formulary. If Eliquis is listed but a coverage exception is needed (e.g., to reduce cost-sharing), the member or prescriber can request a formulary exception, arguing that a lower-tier drug is not medically appropriate for that patient. The prescriber must submit a supporting statement [7].

Low-Income Subsidy (LIS) / Extra Help

Medicare beneficiaries who qualify for the Part D Low-Income Subsidy (Extra Help) pay significantly reduced cost-sharing regardless of the tier. In 2025, full LIS recipients pay no more than $11.20 per month for Tier 3 to 4 drugs [8]. BCBSM MA plan coordinators can assist members in screening for LIS eligibility; income thresholds are approximately 150% of the federal poverty level.

2025 IRA Drug Price Negotiation

The Inflation Reduction Act authorized CMS to negotiate drug prices directly with manufacturers for certain high-spend Medicare drugs. Eliquis was among the first 10 drugs selected for negotiation in August 2023. Negotiated prices for Eliquis take effect January 1, 2026, which may result in lower Tier 3 cost-sharing on BCBSM Medicare Advantage formularies starting in the 2026 plan year [8].

How to Check Your Specific BCBSM Plan's Coverage

Insurance formularies are updated quarterly. What was true in January may change by April. Three reliable methods to confirm current Eliquis coverage under your plan:

1. Log in to the BCBSM member portal at bcbsm.com and use the Drug Formulary Lookup tool with your exact plan name (not just "BCBSM").
2. Call the pharmacy benefits number on the back of your insurance card and ask specifically: "Is apixaban or Eliquis covered, at what tier, and is prior authorization required?"
3. Ask your physician's office to submit a pre-authorization inquiry before writing the prescription. Most prescribers' offices routinely do this for brand-name anticoagulants.

Do not rely on a neighbor's or coworker's experience with "BCBSM." Employer group contracts vary substantially even within the same insurer's network.